NCT00648141

Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis

A 12-Week Symptomatic Effect Evaluation to Compare Celecoxib 200 mg QD, Celecoxib 200 mg BID and Diclofenac 75 mg SR BID in Patients With Ankylosing Spondylitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 458 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To compare the safety and efficacy of once-daily and twice-daily celecoxib versus diclofenac for the treatment of ankylosing spondylitis

Conditions

• Spondylitis, Ankylosing

Interventions

Type	Name	Description
DRUG	Celecoxib	200 mg oral capsule once daily for 12 weeks
DRUG	Celecoxib	200 mg oral capsule twice daily for 12 weeks
DRUG	Diclofenac	75 mg oral capsule twice daily for 12 weeks

Timeline

• Start date: 2003-01-01
• Completion: 2005-01-01
• First posted: 2008-04-01
• Last updated: 2008-04-10

Locations

47 sites across 1 country: Germany